Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Treatment of non - tuberculosis mycobacteria lung disease is challenging. The current treatment used is from 2007 American Thoracic Society guidelines recommended antibiotic combination therapy, which is lack of validation of clinical studies. More and more studies have confirmed that NTM antibiotic resistant gene will affect the efficacy, such as erm(41), rrl to clarithromycin, rrs to amikacin and so on. This study aimed to compare the efficacy of guideline recommended therapy and optimized therapy according to antibiotic susceptibility - related genotype.Genetic testing is accomplished through GenSeizer's high-throughput gene capture technique.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Recommended therapy group | No Intervention | Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results | |
| Optimized therapy group | Experimental | Optimized therapy based on antibiotic resistant genotype test results |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Genotype detected through GenSeizer high-throughput gene capture technology | Diagnostic Test | The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing. |
| Measure | Description | Time Frame |
|---|---|---|
| Culture conversion rate | The proportion of final sputum conversion to culture negative | up to 18 months |
| Measure | Description | Time Frame |
|---|---|---|
| Initial time of sputum culture conversion | The time of first sputum conversion to culture negative | up to 18 months |
| Chest CT | Chest imaging changes of CT examination |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Haiqing Chu, PHD | Contact | +862165115006 | 2112 | chu_haiqing@126.com |
| Bing Li, PHD | Contact | +862165115006 | 2112 | libing044162@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Haiqing Chu | Recruiting | Shanghai | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| up to 18 months |
| Blood routine test | every month, up to 18months |
| liver function test | every month, up to 18months |
| kidney function test | every month, up to 18months |